Related Experiment Video
Updated: Jul 17, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
[Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs]
1Causa Wirtschaftstreuhand GmbH, Wien, Osterreich. office@causa.at
Abstract:
The reimbursement process for pharmaceuticals is increasingly confronted with what is often called "the fourth hurdle". This criterion is required even when therapeutic efficacy, safety and quality have been controlled for. Such a fourth hurdle has also been introduced in Austria in 2002 for the reimbursement of innovative drugs. Despite resistance, it can also be seen as a chance for innovative medicines. By implementing cost/effectiveness analyses it is possible to give a quantitative account of cost/effectiveness advantages. It is however questionable to advocate this procedure in connection with imposing a limiting peak-price.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Clinical Trials: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Preclinical Development: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

